Vaccine Safety and DMT for Highly Active MS: New Data

Many clinicians delay CD20 treatment until vaccine schedules are complete. A study suggests that this precaution may not be necessary.

Related Keywords

Spain ,Emory University ,Georgia ,United States ,Atlanta ,Barcelona ,Comunidad Autonoma De Cataluna ,Hebron ,Israel General ,Israel ,Universitari Vall ,John Cunningham ,Sclerosis Centre Of Catalonia Cemcat ,Department Of Neurology ,Division Of Pediatric Neurology ,Multiple Sclerosis Centre ,Hospital Universitari Vall ,Universitat Aut ,Medscape Medical ,Barcelona Treatment ,Expanded Disability Status Scale ,Medscape Medical News ,Grace Gombolay ,Pediatric Neurology ,Pediatric Neuroimmunology ,Multiple Sclerosis Clinic ,Multiple Sclerosis Ms ,S Multiple Sclerosis ,Immunizations ,Vaccination ,Covid 19 Vaccine ,Coronavirus Vaccine ,Vaccine ,Vaccines ,Hepatitisb Hbv Virus ,Gbv ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Covid 19 ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc43 ,Uman Coronavirus 229e ,Cov 229e ,